Analysis Tools|
Allele Symbol Allele Name Allele ID |
Tg(Tal1-cre/ERT)1Jrg transgene insertion 1, Joachim R Gothert MGI:3055721 |
||||||||||||||||||||
| Summary |
4 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• B16 cell transmigration is considerably reduced after treatment with 4-hydroxytamoxifen
• significantly reduced B16 melanoma lung metastasis after treatment with 4-hydroxytamoxifen
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• tamoxifen-treated mice show multiple arteriovenous (AV) shunts in the ear and skin wound areas
|
|
• tamoxifen-treated mice exhibit arteriovenous malformations in gastrointestinal tract
|
|
• tamoxifen-treated mice exhibit severe hemorrhages in the cecum
|
|
• tamoxifen-treated mice show multiple arteriovenous (AV) shunts in the ear and skin wound areas
• vessels associated with AV shunts are tortuous, enlarged, and present characteristic loops
|
|
• tamoxifen-treated mice exhibit arteriovenous malformations in gastrointestinal tract
|
|
• tamoxifen-treated mice exhibit severe hemorrhages in the cecum
|
|
• tamoxifen-treated mice show multiple arteriovenous (AV) shunts in the ear and skin wound areas
• vessels associated with AV shunts are tortuous, enlarged, and present characteristic loops
|
|
• survival rate is about 2 weeks on average after first tamoxifen injection
• lethality is most likely associated with gastrointestinal hemorrhages
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| hereditary hemorrhagic telangiectasia | DOID:1270 |
OMIM:187300 OMIM:600376 OMIM:601101 OMIM:615506 |
J:227170 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• tamoxifen-injected adults subjected to wounding exhibit multiple arteriovenous (AV) shunts in the punched area of both the ear and the back skin
|
|
• tamoxifen-injected adults subjected to wounding exhibit tortuous and enlarged blood vessels and present multiple arteriovenous (AV) shunts in the punched area of both the ear and the back skin
• however, tamoxifen-treated mice do not exhibit signs of hemorrhages or arteriovenous malformations in internal organs and survive longer than a month
|
|
• tamoxifen-injected adults subjected to wounding exhibit tortuous and enlarged blood vessels and present multiple arteriovenous (AV) shunts in the punched area of both the ear and the back skin
• however, tamoxifen-treated mice do not exhibit signs of hemorrhages or arteriovenous malformations in internal organs and survive longer than a month
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice administered tamoxifen from P1 to P2 show an approximate 2-fold increase in the number of mitotic cells per field in the retina
|
|
• mice administered tamoxifen from P1 to P3 exhibit increased vascular branching and endothelial cell coverage in P5 retinas
|
|
• at 3-4 months after tamoxifen administration, nearly 50% of mice develop liver tumors and by 6-8 months after tamoxifen, almost all mice develop liver tumors
|
|
• small metastatic nodules are seen in the lymphatic vessels near primary tumors of tamoxifen treated mice
• macrometastases are commonly present in lymph nodes and seen in distant sites such as the sternal musculature at lower frequencies
|
|
• mice administered tamoxifen at 2 months of age develop endothelial proliferative lesions from vascular malformations that lead to vascular tumors (angiosarcoma/lymphangiosarcoma); cutaneous tumors in tails and paws and liver tumors develop at 3 months or more after tamoxifen treatment
• cutaneous tumors are also seen on the lips and legs at later time points
• at 3-4 months and 6-8 months after tamoxifen administration, about 30% and 80% of mice develop cutaneous tumors, respectively
• poorly differentiated cutaneous lymphangiosarcomas are highly invasive
• mice treated with rapamycin starting 1 week after tamoxifen administration, do not develop cutaneous or liver tumors
• mice treated with rapamycin after the formation of tumors at 3 months after tamoxifen administration show halted tumor progression and even reduced tumor size and improved survival
• mice treated with axitinib after the formation of tumors at 5 months after tamoxifen show decreased proliferation of tumors, however tumors do not shrink and the number of apoptotic cells remains similar to untreated mice
|
|
• cutaneous tumors are seen on paws and legs of tamoxifen treated mice
• poorly differentiated cutaneous lymphangiosarcomas on the extremities show local invasion into bone
|
|
• mice administered tamoxifen from P1 to P3 exhibit increased vascular branching and endothelial cell coverage in P5 retinas
|
|
• mice administered tamoxifen from P1 to P3 exhibit increased vascular branching and endothelial cell coverage in P5 retinas
|
|
• 1 month after tamoxifen administration, some mice develop edema, with swelling in paws and tails
|
|
• at 3-4 months after tamoxifen administration, nearly 50% of mice develop liver tumors and by 6-8 months after tamoxifen, almost all mice develop liver tumors
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 11/12/2024 MGI 6.24 |
|
|
|
||
